drugset / Trial / NCT07432698
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants
Phase 1
Not yet recruiting
32 enrolled
Shanghai Ark Biopharmaceutical Co., Ltd.
Ark Biosciences Pty Ltd. · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study is a phase I, single-center, randomized, double-blind, placebo-controlled study of AK0406 as a first-in-human (FIH) trial to evaluate the safety, tolerability and pharmacokinetics (PK) of AK0406 in healthy adult participants.
Timeline
- Start
- 2026-02
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK0406 | Unknown | 150 mg | Subcutaneous |
| Subject | AK0406 | Unknown | 300 mg | Subcutaneous |
| Subject | AK0406 | Unknown | 600 mg | Subcutaneous |
| Subject | AK0406 | Unknown | 900 mg | Subcutaneous |
Indications
No indication recorded.